Akari Therapeutics PLC Stock Price, News & Analysis (NASDAQ:AKTX)

$4.65 0.27 (6.16 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$4.38
Today's Range$4.41 - $4.90
52-Week Range$3.18 - $22.20
Volume291,962 shs
Average Volume379,273 shs
Market Capitalization$66.83 million
P/E RatioN/A
Dividend YieldN/A
Beta-8.76

About Akari Therapeutics PLC (NASDAQ:AKTX)

Akari Therapeutics PLC logoAkari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. Its lead drug, Coversin, a complement inhibitor, acts on complement C5, preventing release of C5a and formation of C5b-9. Coversin is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response. It is conducting Phase Ib clinical trial of Coversin. It focuses on rare and orphan diseases, including disease states spanning hematology, nephrology, transplantation, neurology and ophthalmology.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Bio Therapeutic Drugs
  • Symbol: NASDAQ:AKTX
  • CUSIP: N/A
  • Web: akaritx.com
Debt:
  • Current Ratio: 3.48%
  • Quick Ratio: 3.48%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $2.90 per share
  • Price / Book: 1.60
Profitability:
  • Trailing EPS: ($1.84)
  • Net Income: ($18,140,000.00)
  • Return on Equity: -77.39%
  • Return on Assets: -55.94%
Misc:
  • Employees: 15
  • Outstanding Shares: 11,780,000
 
Frequently Asked Questions for Akari Therapeutics PLC (NASDAQ:AKTX)

What is Akari Therapeutics PLC's stock symbol?

Akari Therapeutics PLC trades on the NASDAQ under the ticker symbol "AKTX."

Where is Akari Therapeutics PLC's stock going? Where will Akari Therapeutics PLC's stock price be in 2017?

3 analysts have issued 1 year target prices for Akari Therapeutics PLC's stock. Their forecasts range from $2.50 to $15.00. On average, they expect Akari Therapeutics PLC's share price to reach $8.75 in the next year. View Analyst Ratings for Akari Therapeutics PLC.

What are Wall Street analysts saying about Akari Therapeutics PLC stock?

Here are some recent quotes from research analysts about Akari Therapeutics PLC stock:

  • 1. According to Zacks Investment Research, "Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company's lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5, preventing release of C5a and formation of C5b-9. Akari Therapeutics PLC, formerly known as Celsus Therapeutics Plc, is based in London, United Kingdom. " (11/13/2017)
  • 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: September 21, 2017, 23:12 ET Date and time of production: September 21, 2017, 20:41 ET Target Price / Valuation Methodology: Impax Laboratories – IPXL Our $19 price target is derived from a blend of DCF (7.7% WACC, +1% terminal growth) and a 9.2x forward EV/EBITDA on our 2018 estimates. IPXL shares currently trade around 8x our 2018 EV/EBITDA compared to a group average of around 9.2x. We think a group average EV/EBITDA valuation is warranted because of potential P&L leverage growing profitability faster than revenue which warrants a premium, a premium warranted for the company’s well-respected leadership offset by a discount to the group for relatively low expected top-line growth and a low-duration FTF/FTM based generics pipeline." (9/22/2017)
  • 3. Chardan Capital analysts commented, "We are very proud of the continued advancement of our Coversin program for the treatment of PNH in patients with or without polymorphisms," Gur Roshwalb, CEO of Akari Therapeutics said in a press release. "The FDA fast track designation recognizes the unmet need in patients with PNH who cannot be treated with the current standard of care due to polymorphisms."Not So FastKumar pointed out a 2014 study, which found that only 3.2 percent of PNH patients had Soliris resistance mutations. Moreover, for a disease with an incidence rate of 1.3 per million, Soliris-resistant PNH represents just 10 to 20 patients in the US per year.As such, the analyst emphasized that Akari's designation represents "an extremely limited subset of PNH patients" (4/17/2017)

Who are some of Akari Therapeutics PLC's key competitors?

Who are Akari Therapeutics PLC's key executives?

Akari Therapeutics PLC's management team includes the folowing people:

  • Ray Prudo M.D., Chairman of the Board
  • David Horn Solomon, Chief Executive Officer (Age 57)
  • Dov Elefant, Chief Financial Officer (Age 47)
  • Clive Richardson, Chief Operating Officer, Director
  • Nigel A.S. Hernandez Ph.D., Vice President - Worldwide Regulatory Affairs
  • David Byrne, Director
  • Robert E. Ward, Director (Age 59)
  • Donald A. Williams, Director (Age 57)
  • James Hill M.D., Non-Executive Director
  • Stuart Ungar M.D., Non-Executive Director

Who owns Akari Therapeutics PLC stock?

Akari Therapeutics PLC's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Hikari Power Ltd (1.28%). View Institutional Ownership Trends for Akari Therapeutics PLC.

Who bought Akari Therapeutics PLC stock? Who is buying Akari Therapeutics PLC stock?

Akari Therapeutics PLC's stock was purchased by a variety of institutional investors in the last quarter, including Hikari Power Ltd. View Insider Buying and Selling for Akari Therapeutics PLC.

How do I buy Akari Therapeutics PLC stock?

Shares of Akari Therapeutics PLC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Akari Therapeutics PLC's stock price today?

One share of Akari Therapeutics PLC stock can currently be purchased for approximately $4.65.

How big of a company is Akari Therapeutics PLC?

Akari Therapeutics PLC has a market capitalization of $66.83 million. The biopharmaceutical company earns ($18,140,000.00) in net income (profit) each year or ($1.84) on an earnings per share basis. Akari Therapeutics PLC employs 15 workers across the globe.

How can I contact Akari Therapeutics PLC?

Akari Therapeutics PLC's mailing address is 24 W 40th St Fl 8, NEW YORK, NY 10018-1028, United States. The biopharmaceutical company can be reached via phone at +1-646-3500702 or via email at [email protected]


MarketBeat Community Rating for Akari Therapeutics PLC (NASDAQ AKTX)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  69 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  131
MarketBeat's community ratings are surveys of what our community members think about Akari Therapeutics PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Ratings for Akari Therapeutics PLC (NASDAQ:AKTX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 2 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $8.75 (88.17% upside)
Consensus Price Target History for Akari Therapeutics PLC (NASDAQ:AKTX)
Price Target History for Akari Therapeutics PLC (NASDAQ:AKTX)
Analysts' Ratings History for Akari Therapeutics PLC (NASDAQ:AKTX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/22/2017Canaccord GenuityReiterated RatingBuy$15.00LowView Rating Details
9/22/2017William BlairUpgradeMarket Perform -> OutperformHighView Rating Details
9/17/2017Chardan CapitalReiterated RatingNeutralLowView Rating Details
(Data available from 11/17/2015 forward)

Earnings

Earnings History for Akari Therapeutics PLC (NASDAQ:AKTX)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Akari Therapeutics PLC (NASDAQ:AKTX)
2017 EPS Consensus Estimate: ($2.92)
2018 EPS Consensus Estimate: ($0.04)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.54)($0.54)($0.54)
Q2 20171($0.70)($0.70)($0.70)
Q3 20171($0.77)($0.77)($0.77)
Q4 20171($0.91)($0.91)($0.91)
Q1 20181($0.01)($0.01)($0.01)
Q2 20181($0.01)($0.01)($0.01)
Q3 20181($0.01)($0.01)($0.01)
Q4 20181($0.01)($0.01)($0.01)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Akari Therapeutics PLC (NASDAQ:AKTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Akari Therapeutics PLC (NASDAQ AKTX)
Insider Ownership Percentage: 61.80%
Institutional Ownership Percentage: 26.97%
Insider Trades by Quarter for Akari Therapeutics PLC (NASDAQ:AKTX)
Institutional Ownership by Quarter for Akari Therapeutics PLC (NASDAQ:AKTX)
Insider Trades by Quarter for Akari Therapeutics PLC (NASDAQ AKTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/18/2015Mark S CohenDirectorBuy1,055,600$0.19$200,564.00View SEC Filing  
4/15/2014Sabby Management, LlcMajor ShareholderBuy20,100$5.03$101,103.00View SEC Filing  
4/11/2014Sabby Management, LlcMajor ShareholderBuy2,575$5.35$13,776.25View SEC Filing  
4/8/2014Sabby Management, LlcMajor ShareholderBuy68,404$5.59$382,378.36View SEC Filing  
4/2/2014Sabby Management, LlcMajor ShareholderBuy28,207$6.22$175,447.54View SEC Filing  
3/27/2014Sabby Management, LlcMajor ShareholderBuy16,203$6.66$107,911.98View SEC Filing  
3/24/2014Sabby Management, LlcMajor ShareholderBuy11,100$6.83$75,813.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Akari Therapeutics PLC (NASDAQ:AKTX)
Latest Headlines for Akari Therapeutics PLC (NASDAQ AKTX)
Source:
DateHeadline
FY2017 Earnings Estimate for Akari Therapeutics PLC Issued By William Blair (AKTX)FY2017 Earnings Estimate for Akari Therapeutics PLC Issued By William Blair (AKTX)
www.americanbankingnews.com - November 17 at 9:44 PM
Akari Therapeutics PLC (AKTX) Upgraded at Zacks Investment ResearchAkari Therapeutics PLC (AKTX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - November 13 at 8:30 PM
 Akari Therapeutics PLC (AKTX) Given Average Rating of "Buy" by Analysts Akari Therapeutics PLC (AKTX) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - November 13 at 3:03 PM
Comparing Akari Therapeutics PLC (AKTX) and The CompetitionComparing Akari Therapeutics PLC (AKTX) and The Competition
www.americanbankingnews.com - November 8 at 9:34 PM
Analyzing Akari Therapeutics PLC (AKTX) and The CompetitionAnalyzing Akari Therapeutics PLC (AKTX) and The Competition
www.americanbankingnews.com - October 31 at 11:10 PM
Akari Therapeutcis (AKTX) Prices 3.48M ADS Offering at $5/ShAkari Therapeutcis (AKTX) Prices 3.48M ADS Offering at $5/Sh
www.streetinsider.com - October 19 at 4:15 PM
Akari Therapeutics Announces Pricing of Public Offering of American Depositary SharesAkari Therapeutics Announces Pricing of Public Offering of American Depositary Shares
finance.yahoo.com - October 18 at 4:54 PM
Zacks Investment Research Lowers Akari Therapeutics PLC (AKTX) to SellZacks Investment Research Lowers Akari Therapeutics PLC (AKTX) to Sell
www.americanbankingnews.com - October 17 at 9:02 PM
Akari Therapeutics Announces Proposed Public Offering of American Depositary SharesAkari Therapeutics Announces Proposed Public Offering of American Depositary Shares
finance.yahoo.com - October 17 at 4:35 PM
Corporate News Blog - Akari Therapeutics Announces Enrolment of Additional Patients in COBALT Phase-II Clinical Trial of Coversin(TM)Corporate News Blog - Akari Therapeutics Announces Enrolment of Additional Patients in COBALT Phase-II Clinical Trial of Coversin(TM)
finance.yahoo.com - October 13 at 3:38 PM
 Brokerages Expect Akari Therapeutics PLC (AKTX) Will Post Earnings of -$1.00 Per Share Brokerages Expect Akari Therapeutics PLC (AKTX) Will Post Earnings of -$1.00 Per Share
www.americanbankingnews.com - October 12 at 4:20 PM
Akari Therapeutics Announces Further Clinical ProgressAkari Therapeutics Announces Further Clinical Progress
finance.yahoo.com - October 11 at 5:15 PM
Akari Therapeutics PLC (AKTX) Expected to Announce Earnings of -$0.77 Per ShareAkari Therapeutics PLC (AKTX) Expected to Announce Earnings of -$0.77 Per Share
www.americanbankingnews.com - September 24 at 12:18 AM
Akari Therapeutics PLC (AKTX) Receives Buy Rating from Canaccord GenuityAkari Therapeutics PLC (AKTX) Receives Buy Rating from Canaccord Genuity
www.americanbankingnews.com - September 22 at 9:38 PM
Akari Therapeutics Announces Regulatory Progress Following FDA MeetingAkari Therapeutics Announces Regulatory Progress Following FDA Meeting
finance.yahoo.com - September 22 at 7:50 PM
Akari Therapeutics (AKTX) Stock is Skyrocketing Over 60% Today: Here's WhyAkari Therapeutics (AKTX) Stock is Skyrocketing Over 60% Today: Here's Why
finance.yahoo.com - September 22 at 7:50 PM
Akari Therapeutics Rally Continues As William Blair UpgradesAkari Therapeutics Rally Continues As William Blair Upgrades
finance.yahoo.com - September 22 at 7:50 PM
Akari Therapeutics PLC (AKTX) Raised to "Outperform" at William BlairAkari Therapeutics PLC (AKTX) Raised to "Outperform" at William Blair
www.americanbankingnews.com - September 22 at 9:18 AM
Akari Therapeutics PLC (AKTX) Given Neutral Rating at Chardan CapitalAkari Therapeutics PLC (AKTX) Given Neutral Rating at Chardan Capital
www.americanbankingnews.com - September 20 at 6:26 AM
Akari Therapeutics to Present at the Cantor Fitzgerald Global Healthcare ConferenceAkari Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 19 at 3:43 PM
Contrasting Akari Therapeutics PLC (AKTX) & MEI Pharma (MEIP)Contrasting Akari Therapeutics PLC (AKTX) & MEI Pharma (MEIP)
www.americanbankingnews.com - September 19 at 12:36 PM
Idera Pharmaceuticals (IDRA) Jumps: Stock Rises 14.4%Idera Pharmaceuticals (IDRA) Jumps: Stock Rises 14.4%
finance.yahoo.com - September 12 at 3:55 PM
Merus (MRUS) Looks Good: Stock Adds 5.8% in SessionMerus (MRUS) Looks Good: Stock Adds 5.8% in Session
finance.yahoo.com - September 11 at 4:33 PM
NewLink Genetics (NLNK) Jumps: Stock Rises 29.9%NewLink Genetics (NLNK) Jumps: Stock Rises 29.9%
finance.yahoo.com - September 11 at 4:33 PM
Regenxbio (RGNX) in Focus: Stock Moves 9.5% HigherRegenxbio (RGNX) in Focus: Stock Moves 9.5% Higher
finance.yahoo.com - September 6 at 3:39 PM
BioMarin (BMRN) in Focus: Stock Moves 5.6% HigherBioMarin (BMRN) in Focus: Stock Moves 5.6% Higher
www.zacks.com - August 31 at 3:34 PM
European ADRs Nudge Lower in Wednesday SessionEuropean ADRs Nudge Lower in Wednesday Session
www.nasdaq.com - August 24 at 1:49 AM
Akari Therapeutics Announces Appointment of David Horn Solomon as CEOAkari Therapeutics Announces Appointment of David Horn Solomon as CEO
finance.yahoo.com - August 21 at 3:52 PM
 Analysts Anticipate Akari Therapeutics PLC (AKTX) Will Announce Earnings of -$0.70 Per Share Analysts Anticipate Akari Therapeutics PLC (AKTX) Will Announce Earnings of -$0.70 Per Share
www.americanbankingnews.com - August 17 at 6:18 PM
Chardan Capital Reiterates "Neutral" Rating for Akari Therapeutics PLC (AKTX)Chardan Capital Reiterates "Neutral" Rating for Akari Therapeutics PLC (AKTX)
www.americanbankingnews.com - August 11 at 5:02 PM
Akari Therapeutics to Present at the 37th Annual Canaccord Genuity Growth ConferenceAkari Therapeutics to Present at the 37th Annual Canaccord Genuity Growth Conference
finance.yahoo.com - August 10 at 5:09 PM
European ADRs Fractionally Higher as Banks See Mixed FortunesEuropean ADRs Fractionally Higher as Banks See Mixed Fortunes
www.nasdaq.com - August 1 at 1:57 AM
Akari Therapeutics PLC (AKTX) Expected to Announce Earnings of -$0.70 Per ShareAkari Therapeutics PLC (AKTX) Expected to Announce Earnings of -$0.70 Per Share
www.americanbankingnews.com - July 30 at 12:15 PM
FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Akari Therapeutics Plc (AKTX) and Lead Plaintiff Deadline - - July 11, 2017FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Akari Therapeutics Plc (AKTX) and Lead Plaintiff Deadline - - July 11, 2017
finance.yahoo.com - July 11 at 4:56 PM
DEADLINE TOMORROW: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Akari Therapeutics, Plc and Reminds Investors with Losses Exceeding $100,000 to Contact the FirmDEADLINE TOMORROW: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Akari Therapeutics, Plc and Reminds Investors with Losses Exceeding $100,000 to Contact the Firm
finance.yahoo.com - July 10 at 3:38 PM
DEADLINE TOMORROW: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Akari Therapeutics, Plc and Reminds Investors with Losses Exceeding $100,000 to Contact the FirmDEADLINE TOMORROW: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Akari Therapeutics, Plc and Reminds Investors with Losses Exceeding $100,000 to Contact the Firm
finance.yahoo.com - July 10 at 3:38 PM
European ADRs Move Lower in Friday TradingEuropean ADRs Move Lower in Friday Trading
www.nasdaq.com - July 8 at 8:01 AM
AKARI THERAPEUTICS 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class ...AKARI THERAPEUTICS 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class ...
www.businesswire.com - July 8 at 8:01 AM
AKARI THERAPEUTICS 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit against Akari Therapeutics, Plc – (AKTX)AKARI THERAPEUTICS 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit against Akari Therapeutics, Plc – (AKTX)
finance.yahoo.com - July 8 at 8:01 AM
JULY 11 DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Akari Therapeutics, Plc and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmJULY 11 DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Akari Therapeutics, Plc and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
finance.yahoo.com - July 8 at 8:01 AM
July 11 Deadline Alert: GPM Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akari Therapeutics, PlcJuly 11 Deadline Alert: GPM Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akari Therapeutics, Plc
finance.yahoo.com - July 7 at 6:01 PM
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Akari Therapeutics Plc (AKTX) and Lead Plaintiff Deadline - - July 11, 2017DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Akari Therapeutics Plc (AKTX) and Lead Plaintiff Deadline - - July 11, 2017
finance.yahoo.com - July 7 at 6:01 PM
DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Akari Therapeutics, Plc and Reminds Investors with Losses In Excess of $100,000 to Contact the FirmDEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Akari Therapeutics, Plc and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm
finance.yahoo.com - July 6 at 10:04 PM
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Akari Therapeutics Plc (AKTX) & Lead Plaintiff Deadline - July 11, 2017DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Akari Therapeutics Plc (AKTX) & Lead Plaintiff Deadline - July 11, 2017
finance.yahoo.com - July 6 at 5:02 PM
5-DAY ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Akari Therapeutics, Plc and Reminds Investors with Losses Exceeding $100,000 to Contact the Firm5-DAY ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Akari Therapeutics, Plc and Reminds Investors with Losses Exceeding $100,000 to Contact the Firm
finance.yahoo.com - July 6 at 5:02 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akari Therapeutics plc of Class Action Lawsuit and Upcoming Deadline - AKTXSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akari Therapeutics plc of Class Action Lawsuit and Upcoming Deadline - AKTX
finance.yahoo.com - July 4 at 5:47 PM
EQUITY ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Akari Therapeutics, Plc and Reminds Investors with Losses Exceeding $100,000 to Contact the FirmEQUITY ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Akari Therapeutics, Plc and Reminds Investors with Losses Exceeding $100,000 to Contact the Firm
finance.yahoo.com - July 3 at 8:38 PM
INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Akari Therapeutics Plc (AKTX) & Lead Plaintiff Deadline - July 11, 2017INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Akari Therapeutics Plc (AKTX) & Lead Plaintiff Deadline - July 11, 2017
finance.yahoo.com - July 3 at 3:37 PM
APPROACHING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Akari Therapeutics, Plc and Reminds Investors with Losses In Excess of $100,000 to Contact the FirmAPPROACHING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Akari Therapeutics, Plc and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm
finance.yahoo.com - July 1 at 1:59 AM
AKARI THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline ...AKARI THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline ...
www.businesswire.com - June 17 at 2:06 AM

Social Media

Financials

Chart

Akari Therapeutics PLC (NASDAQ AKTX) Chart for Friday, November, 17, 2017
Loading chart…

This page was last updated on 11/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.